Clinical Trial: Ameparomo Capsules 250 mg Drug Use Investigation

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Observational

Official Title: Drug Use Investigation Of Paromomycin. (Regulatory Post Marketing Commitment Plan).

Brief Summary: This Study is intended to evaluate the safety and effectiveness of Ameparomo Capsules 250 mg under actual medical practice.

Detailed Summary:
Sponsor: Pfizer

Current Primary Outcome: Number of Paticipants With Adverse Events (AEs) by Seriousness and Relationship to Treatment [ Time Frame: Maximum 10 days ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Number of Participants With Clinical Response of Cure [ Time Frame: Maximum 3 months ]

Original Secondary Outcome: Same as current

Information By: Pfizer

Dates:
Date Received: February 9, 2016
Date Started: October 2015
Date Completion: September 2019
Last Updated: May 2, 2017
Last Verified: May 2017